BioCentury
ARTICLE | Company News

Hyperion Therapeutics Inc, Horizon Pharma deal

April 6, 2015 7:00 AM UTC

Last June, EMA accepted for review an MAA for Ravicti to treat UCD; Hyperion expects a decision from EMA’s CHMP in late 2015 or early 2016. Hyperion plans to submit an sNDA for Ravicti to treat UCD in...